1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797632811848433664 |
|---|---|
| author | Violeta Sánchez Justin M Balko Elizabeth Wescott Melinda Sanders Xiaopeng Sun Susan Opalenik Brandie C Taylor Paula Gonzalez Ericsson Ann Hanna Brian Lehmann Vandana Abramson Jennifer Pietenpol |
| author_facet | Violeta Sánchez Justin M Balko Elizabeth Wescott Melinda Sanders Xiaopeng Sun Susan Opalenik Brandie C Taylor Paula Gonzalez Ericsson Ann Hanna Brian Lehmann Vandana Abramson Jennifer Pietenpol |
| author_sort | Violeta Sánchez |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:43:04Z |
| format | Article |
| id | doaj.art-f9030f8e8b5948d8aaf7981c539e286a |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:43:04Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-f9030f8e8b5948d8aaf7981c539e286a2023-11-09T22:35:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.10021002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancerVioleta Sánchez0Justin M Balko1Elizabeth Wescott2Melinda Sanders3Xiaopeng Sun4Susan Opalenik5Brandie C Taylor6Paula Gonzalez Ericsson7Ann Hanna8Brian Lehmann9Vandana Abramson10Jennifer Pietenpol11Vanderbilt University, Nashville, TN, United States11 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USAVanderbilt University, Nashville, TN, United StatesVanderbilt University, Nashville, TN, United StatesVanderbilt University Medical Center, Nashville, TN, United States1Vanderbilt University, Nashville, TN, United States1Vanderbilt University, Nashville, TN, USA2Vanderbilt University Medical Center, Nashville, TN, USA2Vanderbilt University Medical Center, Nashville, TN, USA2Vanderbilt University Medical Center, Nashville, TN, USA3Vanderbilt University School of Medicine, Nashville, TN, USA3Vanderbilt University School of Medicine, Nashville, TN, USA |
| spellingShingle | Violeta Sánchez Justin M Balko Elizabeth Wescott Melinda Sanders Xiaopeng Sun Susan Opalenik Brandie C Taylor Paula Gonzalez Ericsson Ann Hanna Brian Lehmann Vandana Abramson Jennifer Pietenpol 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer Journal for ImmunoTherapy of Cancer |
| title | 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer |
| title_full | 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer |
| title_fullStr | 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer |
| title_full_unstemmed | 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer |
| title_short | 1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer |
| title_sort | 1002 intratumor heterogeneity in mhc i expression drives immunotherapy resistance and exposes nkg2a as a therapeutic target in breast cancer |
| work_keys_str_mv | AT violetasanchez 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT justinmbalko 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT elizabethwescott 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT melindasanders 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT xiaopengsun 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT susanopalenik 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT brandiectaylor 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT paulagonzalezericsson 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT annhanna 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT brianlehmann 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT vandanaabramson 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer AT jenniferpietenpol 1002intratumorheterogeneityinmhciexpressiondrivesimmunotherapyresistanceandexposesnkg2aasatherapeutictargetinbreastcancer |